American Association for Cancer Research

Continuing Medical Education

Advances in Prostate Cancer Research


The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.


The AACR has designated this live activity for a maximum of 19.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.


Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Tuesday, March 4, 2014. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.


Prostate cancer is the most common cancer in men and the second-leading cause of cancer death. In 2013, about 238,590 new prostate cancer cases are expected to be diagnosed in the United States alone and an estimated 29,720 Americans are expected to die from the disease (ACS Facts & Figures 2013).  The probability of developing prostate cancer increases dramatically for men over 40 years of age. In addition to increasing age, race and family history/genetics are risk factors. There is also evidence that diet, sedentary lifestyle, and obesity may increase risk for disease.  

Prostate-specific antigen has been used as diagnostic marker for prostate cancer since the mid-1980s, but advances in technology and new insights into genetic susceptibility and pathogenesis of aggressive versus slow-growing prostate cancer have the potential to have a major impact in how the disease is treated in each patient.

There is a need to bring together basic researchers, physicians, clinician-scientists, and population scientists to discuss the latest advances in prostate cancer research and to educate physicians and health practitioners about how they can apply these advances to improve screening and prevention strategies for individuals at risk for developing the disease and treatment or disease management for individuals diagnosed with prostate cancer. Therefore, a focus of this conference will be to educate physicians on timely topics including prevention strategies, risk assessment, screening guidelines, risk assessment, disease management, and treatment.

After participating in this CME activity, physicians should be able to:

  • Utilize novel biomarkers and genomics in a precision-medicine approach to recommending treatment or active surveillance;
  • Identify novel agents, including those focusing on advanced prostate cancer and castration-resistant prostate cancer that are in development and their potential applications in clinical settings;
  • Explain advances in using prostate cancer models to further elucidate prostate cancer pathogenesis, metastasis, and regulatory pathways;
  • Critically assess the results of cancer prevention studies to evaluate if preventive interventions are appropriate for populations at increased risk for prostate cancer;
  • Explain mechanisms of resistance for current treatments for aggressive prostate cancer; and
  • Evaluate the role of metabolism and lifestyle factors such as exercise and diet in determining prostate cancer risk and outcomes.


It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.


This activity is supported by grants and will be disclosed at the activity.


Please contact the Office of CME at 215-440-9300 or